Hottest News: Corrections Corporation of America (NYSE:CXW), A. Schulman (NASDAQ:SHLM), MeetMe (NASDAQ:MEET), OncoGenex Pharmaceuticals (NASDAQ:OGXI)

Las Vegas Sands Corp. (NYSE:LVS) shares decreased -3.07% in last trading session and ended the day at $42.69. LVS Gross Margin is 47.50% and its has a return on assets of 10.40%. Las Vegas Sands Corp. (NYSE:LVS) quarterly performance is -3.38%.

Corrections Corporation of America (NYSE:CXW) ended the last trading day at $27.59. Company weekly volatility is calculated as 2.95% and price to cash ratio as 41.25. Corrections Corporation of America (NYSE:CXW) showed a weekly performance of 2.49%.

Corrections Corporation of America (NYSE:CXW) announced that its Board of Directors declared a quarterly dividend of $0.54 per share to be paid on January 15, 2016 to shareholders of record as of the close of business on January 4, 2016.

On 06 January, A. Schulman, Inc. (NASDAQ:SHLM) shares increased 1.17% and was closed at $29.30. SHLM EPS growth in last 5 year was -13.50%. A. Schulman, Inc. (NASDAQ:SHLM) year to date (YTD) performance is -4.37%.

A. Schulman, Inc. (NASDAQ:SHLM) expects to release fiscal 2016 first-quarter results prior to market open on Monday, January 11, 2016. The Company will hold its fiscal 2016 first-quarter earnings conference call that same day at 10 a.m. Eastern time, with Bernard Rzepka, President and Chief Executive Officer and Joseph Levanduski, Executive Vice President and Chief Financial Officer.

MeetMe, Inc. (NASDAQ:MEET) shares increased 10.53% in last trading session and ended the day at $3.93. MEET has a return on assets of 0.70%. MeetMe, Inc. (NASDAQ:MEET) quarterly performance is 137.05%.

MeetMe, Inc. (NASDAQ:MEET), raised its full year 2015 financial guidance for the year ended December 31, 2015 in advance of a non-deal roadshow with potential investors. Total revenue is expected to be approximately $56.5 million, an increase of 26% from full year 2014, and above the Company’s previously released guidance range of $53.5 million to $54 million for full year 2015. Adjusted EBITDA is expected to be approximately $19.5 million, an increase of 289% from the prior year, and above the previously released guidance range of $16.5 million to $17.5 million for full year 2015.

OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) caters to the Healthcare space. On the last day of trading company shares ended up at $1.18. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) distance from 50-day simple moving average (SMA50) is -5.46%.

Zacks Investment Research lowered shares of OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) from a buy rating to a hold rating in a research note released on Friday, ARN reports.